MX2022000484A - Anticuerpos contra bssl novedosos. - Google Patents

Anticuerpos contra bssl novedosos.

Info

Publication number
MX2022000484A
MX2022000484A MX2022000484A MX2022000484A MX2022000484A MX 2022000484 A MX2022000484 A MX 2022000484A MX 2022000484 A MX2022000484 A MX 2022000484A MX 2022000484 A MX2022000484 A MX 2022000484A MX 2022000484 A MX2022000484 A MX 2022000484A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
binding fragments
novel
hbssl
Prior art date
Application number
MX2022000484A
Other languages
English (en)
Inventor
Olle Hernell
Susanne Lindquist
Lennart Lundberg
Lotsholm Helena Persson
Original Assignee
Lipum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipum Ab filed Critical Lipum Ab
Publication of MX2022000484A publication Critical patent/MX2022000484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase

Abstract

La presente invención se refiere a anticuerpos aislados novedosos y fragmentos de unión al antígeno de estos que se unen a la lipasa estimulada por sales biliares humana (hBSSL). Los anticuerpos y fragmentos de unión al antígeno de estos se unen a un epítopo previamente no caracterizado, situado en la parte del extremo N de hBSSL e identificado como que comprende los residuos de aminoácidos 7-12 y los residuos de aminoácidos 42-55. La presente invención 5 también se refiere a los usos médicos de los anticuerpos, y/o los fragmentos de unión al antígeno de estos, en particular en el tratamiento de afecciones inflamatorias, y a composiciones farmacéuticas relacionadas.
MX2022000484A 2019-07-12 2020-07-10 Anticuerpos contra bssl novedosos. MX2022000484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950888 2019-07-12
PCT/SE2020/050728 WO2021010888A1 (en) 2019-07-12 2020-07-10 Novel bssl antibodies

Publications (1)

Publication Number Publication Date
MX2022000484A true MX2022000484A (es) 2022-02-03

Family

ID=74210559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000484A MX2022000484A (es) 2019-07-12 2020-07-10 Anticuerpos contra bssl novedosos.

Country Status (11)

Country Link
US (1) US20220267469A1 (es)
EP (1) EP3999115A4 (es)
JP (1) JP2022540859A (es)
KR (1) KR20220034775A (es)
CN (1) CN114096275A (es)
AU (1) AU2020315684A1 (es)
BR (1) BR112022000391A2 (es)
CA (1) CA3146193A1 (es)
IL (1) IL289639A (es)
MX (1) MX2022000484A (es)
WO (1) WO2021010888A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023060137A2 (en) * 2021-10-05 2023-04-13 Board Of Regents, The University Of Texas System Methods and compositions comprising b7-h3 binding polypeptides
WO2024080920A1 (en) 2022-10-14 2024-04-18 Lipum Ab Anti-bssl antibodies for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501939D0 (sv) * 1995-05-24 1995-05-24 Astra Ab DNA molecules for expression of polypeptides
JP5066445B2 (ja) * 2004-03-31 2012-11-07 ユニヴェルシテ・ドゥ・ラ・メディテラネ 膵構造から誘導される糖ペプチド、抗体ならびに診断および治療におけるそれらの応用
EP1840573A1 (en) * 2006-03-27 2007-10-03 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
JP2010532976A (ja) * 2007-06-08 2010-10-21 ユニヴェルシテ・ドゥ・ラ・メディテラネ 膵臓腫瘍を治療するための組成物および方法
US8597650B2 (en) * 2009-04-08 2013-12-03 Olle Hernell Methods for treating rheumatoid arthritis with anti-bile salt-stimulated lipase (BSSL) antibodies
EP3590965A1 (en) * 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP3176185A1 (en) * 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
EP3999115A4 (en) 2023-11-22
CN114096275A (zh) 2022-02-25
IL289639A (en) 2022-03-01
US20220267469A1 (en) 2022-08-25
CA3146193A1 (en) 2021-01-21
EP3999115A1 (en) 2022-05-25
KR20220034775A (ko) 2022-03-18
WO2021010888A1 (en) 2021-01-21
AU2020315684A1 (en) 2021-12-16
JP2022540859A (ja) 2022-09-20
BR112022000391A2 (pt) 2022-03-03

Similar Documents

Publication Publication Date Title
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12019550087A1 (en) Anti-cd73 antibodies and uses thereof
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
CR20190561A (es) ANTICUERPOS ANTI-GARP-TGF-ß
WO2019148026A8 (en) Il-22 fc fusion proteins and methods of use
MX2010003574A (es) Anticuerpos il-23.
MX2022000484A (es) Anticuerpos contra bssl novedosos.
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2019003890A (es) Anticuerpos con union reducida a impurezas de proceso.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2020007628A (es) Composiciones y metodos de uso.
WO2016193872A3 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
CR20220047A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2020097127A3 (en) B-cell activating cd73 antibodies
AU2020378127A8 (en) Compounds as CD73 inhibitors
WO2012029061A3 (en) POLYPEPTIDES DERIVED FROM α-1 ANTITRYPSIN AND METHODS OF USE THEREOF
MX2022001489A (es) Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
MX2013004710A (es) Anticuerpos para el tratamiento de vih.
WO2021024133A3 (en) Biopharmacuetical compositions and related methods
EP4155734A3 (en) Method